With a market cap of $62.4 billion, Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and ...

Regeneron Pharmaceuticals ... The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

The city’s pharma giants avoided much of the initial turbulence felt by the rest of the economy in the wake of President ...

BofA lowered the firm’s price target on Regeneron (REGN) to $547 from $575 and keeps an Underperform rating on the shares based on a lower ...

Canaccord analyst John Newman lowered the firm’s price target on Regeneron (REGN) to $150 from $170 and keeps a Hold rating on the shares. The ...

Regeneron Pharmaceuticals has won U.S. Food and Drug Administration priority review for its application seeking expanded approval of its Eylea HD eye drug.

Shares of Regeneron Pharmaceuticals Inc. REGN rose 1.43% to $554.18 Friday, on what proved to be an all-around great trading ...

FDA accepts Regeneron's sBLA for Eylea HD in RVO with priority review; QUASAR data supports monthly dosing, target action date set for August 2025.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $831.43, with a high estimate of $1013.00 and a low estimate of $547.00. Highlighting a 8.86% ...